证券代码：688513 证券简称：苑东生物 公告编号：2025-059 成都苑东生物制药股份有限公司 二、本次进展情况 关于受让参股公司部分股权暨关联交易完成的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、已披露的受让股权暨关联交易概述 近日，苑东生物投资管理（上海）有限公司已完成对上海超阳部分股权受让款的支付，上海超阳已依法 办理完成本次股权受让所涉及的股权变更工商登记事宜，并取得了上海市闵行区市场监督管理局于2025 年8月21日核发的《营业执照》。本次变更后，上海超阳注册资本不变仍为8,800万元人民币，公司间接 持有上海超阳的股权比例由11.3636%增加至30.6818%，本次交易已完成，上海超阳成为公司施加重大 影响的参股公司。 为更好地实施成都苑东生物制药股份有限公司（以下称"公司"）战略发展规划，加快推进公司创新转型 战略的实施步伐，公司于2025年6月26日召开第四届董事会第五次会议审议通过《关于受让参股公司部 分股权暨关联交易的议案》，同意由公司全资子公司苑东生物投资管理（上海）有限公司 ...

Group 1 - The core viewpoint of the article highlights the movements of social security funds in the stock market, particularly their investments in 18 stocks on the Sci-Tech Innovation Board, with a total holding of 61.6075 million shares valued at 3.172 billion yuan [1][2] - In the second quarter, social security funds entered 5 new stocks, increased holdings in 6 stocks, and reduced holdings in 4 stocks, while 3 stocks remained unchanged in their holdings [1][2] - The stocks with the highest holdings by social security funds include Daotong Technology with 9.2709 million shares, followed by Nanwei Medical and Kaili New Materials with 9.1785 million and 6.3642 million shares respectively [1][2] Group 2 - Among the stocks held by social security funds, 15 companies reported year-on-year net profit growth in the first half of the year, with Rongzhi Rixin showing the highest increase of 2063.42% [2] - The sectors where social security funds are concentrated include pharmaceuticals and biotechnology, electronics, and computers, with 5, 5, and 3 stocks respectively [2] - The average increase in the stock prices of the Sci-Tech Innovation Board stocks held by social security funds since July is 22.09%, with Ding Tong Technology leading at a cumulative increase of 66.39% [2]

Group 1: Zhongtong Express (中通快递) - Profitability under pressure, adjusted net profit for Q2 2025 decreased by 26.8% YoY, with a single ticket net profit of 0.21 CNY, down 12 cents YoY [2][7][10] - Revenue for Q2 2025 reached 11.8 billion CNY, a 10.3% increase YoY, while H1 2025 revenue was 22.7 billion CNY, up 9.8% YoY [7][9] - Market share increased to 19.5% in Q2 2025, with a package volume of 9.85 billion pieces, up 16.5% YoY [9][10] - Capital expenditure for 2025 expected to remain flat or slightly decrease, with H1 2025 capital expenditure at 3.1 billion CNY [9][10] - Mid-term dividend of 0.3 USD per share, with a payout ratio of 40% [9][10] Group 2: Yuanda Pharmaceutical (远大医药) - Revenue for H1 2025 was 6.107 billion HKD, a 1.0% increase YoY, with net profit of 1.169 billion HKD, slightly down by 5.9% YoY [3][12] - The nuclear medicine segment saw a revenue increase of 105.5% YoY, contributing significantly to overall growth [12][13] - Revenue projections for 2025-2027 are 12.254 billion, 13.376 billion, and 14.779 billion HKD, with net profits of 2.185 billion, 2.462 billion, and 2.706 billion HKD respectively [14] Group 3: Yuandong Bio (苑东生物) - H1 2025 revenue was 654 million CNY, down 2.3% YoY, with net profit of 137 million CNY, down 6.8% YoY [4][16] - The company is focusing on self-research and strategic investments to accelerate innovation [16][17] - Revenue projections for 2025-2027 are 1.501 billion, 1.795 billion, and 2.202 billion CNY, with net profits of 282 million, 345 million, and 431 million CNY respectively [18] Group 4: Pop Mart (泡泡玛特) - H1 2025 revenue reached 13.876 billion CNY, a 204.4% increase YoY, with net profit of 4.574 billion CNY, up 396.5% YoY [19][20] - The company is expanding its global presence, with significant growth in the Americas and Asia-Pacific regions [19][20] - Revenue projections for 2025-2027 are 11.128 billion, 15.332 billion, and 20.295 billion CNY, with substantial YoY growth rates [21] Group 5: Nanjing Steel (南钢股份) - H1 2025 revenue was 28.944 billion CNY, down 14.06% YoY, while net profit increased by 18.63% to 1.463 billion CNY [23][24] - High-end products contributed significantly to profit, with advanced steel materials accounting for 29.77% of total sales [24] - The company is expanding its overseas operations, including a new coke production base in Indonesia [24] Group 6: Huayang Group (华阳集团) - H1 2025 revenue was 5.311 billion CNY, a 26.65% increase YoY, with net profit of 341 million CNY, up 18.98% YoY [26][27] - The automotive electronics and precision die-casting segments are driving growth, with significant new orders from major global clients [26][27] - Revenue projections for 2025-2027 are 12.71 billion, 15.89 billion, and 19.17 billion CNY, with net profits of 870 million, 1.15 billion, and 1.43 billion CNY respectively [27] Group 7: Shenhuo Co. (神火股份) - H1 2025 revenue was 20.428 billion CNY, up 12.12% YoY, while net profit decreased by 16.62% to 1.904 billion CNY [29][30] - The aluminum business is the main contributor to revenue, while coal business faced significant price declines [30][31] - Revenue projections for 2025-2027 are 2.41, 2.67, and 2.96 CNY per share, with corresponding PE ratios of 8, 7, and 7 [31] Group 8: Beixin Building Materials (北新建材) - H1 2025 revenue was 13.558 billion CNY, a slight decrease of 0.29% YoY, with net profit down 12.85% [33][34] - The gypsum board business is under pressure, while waterproof and paint businesses are showing growth [34][35] - Revenue projections for 2025-2027 are 3.935 billion, 4.464 billion, and 4.952 billion CNY, with corresponding EPS of 2.33, 2.64, and 2.93 CNY [35]

二、本次进展情况 证券代码：688513 证券简称：苑东生物 公告编号：2025-059 成都苑东生物制药股份有限公司 关于受让参股公司部分股权暨关联交易完成的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、已披露的受让股权暨关联交易概述 为更好地实施成都苑东生物制药股份有限公司（以下称"公司"）战略发展规 划，加快推进公司创新转型战略的实施步伐，公司于 2025 年 6 月 26 日召开第四 届董事会第五次会议审议通过《关于受让参股公司部分股权暨关联交易的议案》， 同意由公司全资子公司苑东生物投资管理（上海）有限公司作为投资主体受让上 海超阳药业有限公司（以下简称"上海超阳"）原股东吴汉超、北京齐力佳科技有 限公司（以下简称"齐力佳"）持有的部分股权，其中，拟以 810 万元人民币受让 吴汉超所持有的上海超阳 7.9545%的股权，对应上海超阳注册资本 700 万元；拟 以 1,158 万元人民币受让齐力佳所持有的上海超阳 11.3636%的股权，对应上海超 阳注册资本 1,000 万元；资金来源均为自有资 ...

开源证券8月21日发布研报称，给予苑东生物（688513.SH，最新价：64.17元）买入评级。评级理由主 要包括：1）公司麻醉业务持续进阶，创新研发驱动成长；2）增持超阳加速研发，新型口服CRBN分子 胶进击BIC。风险提示：集采降价的风险；药品研发失败的风险；产品竞争加剧的风险等。 （文章来源：每日经济新闻） ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's Q2 2025 performance shows significant improvement, with a quarter-on-quarter revenue increase of 14.12% and a net profit increase of 25.40% [4] - The company is expected to continue achieving its stock incentive goals, driven by new product launches and accelerated overseas revenue growth [4] - The projected net profits for 2025-2027 are 271 million, 319 million, and 379 million yuan respectively, with corresponding EPS of 1.53, 1.80, and 2.15 yuan [4] Financial Summary - For H1 2025, the company reported revenue of 654 million yuan (down 2.25% year-on-year) and a net profit of 137 million yuan (down 6.77% year-on-year) [4] - Q2 2025 revenue was 349 million yuan (down 1.61% year-on-year, up 14.12% quarter-on-quarter) and net profit was 76 million yuan (up 6.29% year-on-year, up 25.40% quarter-on-quarter) [4] - The company’s revenue is projected to grow from 1,532 million yuan in 2025 to 2,109 million yuan in 2027, with a year-on-year growth rate of 13.5% and 18.5% respectively [8] Business Development - The company has recently received approvals for new products, including sodium nalbuphine injection and butorphanol tartrate injection, contributing to revenue growth [5] - The company is actively expanding its international market presence, with regular shipments of nicardipine hydrochloride injection and plans for a naloxone nasal spray submission in September 2024 [5] - The company has increased its stake in Chao Yang to 30.68%, enhancing its innovation platform value [6]

Investment Rating - The report maintains an "Accumulate" rating for the company [4][10] Core Views - The company's performance is under short-term pressure due to the implementation of centralized procurement, with a revenue of 654 million yuan in the first half of 2025, down 2.3%, and a net profit of 137 million yuan, down 6.8% [1][4] - The company is advancing its innovation transformation through self-research and strategic investments, with multiple new drugs making clinical progress [2][3] Financial Performance Summary - In the first half of 2025, the company reported a revenue of 654 million yuan, a decrease of 2.3%, and a net profit of 137 million yuan, a decrease of 6.8%. The gross margin was 75.81%, down 1.9 percentage points, and the net margin was 20.87%, down 1.0 percentage points [1][4] - For Q2 2025, revenue was 349 million yuan, down 1.7%, while net profit increased by 7.0% to 76 million yuan [1] - The company’s expense ratios included a sales expense ratio of 31.64% (down 3.7 percentage points), a management expense ratio of 6.91% (up 0.4 percentage points), and a research and development expense ratio of 19.79% (up 3.5 percentage points) [1] Innovation and Strategic Investment Summary - The company has made progress in its self-research pipeline, with several new drugs receiving clinical approvals, including small molecule drugs EP-0108, EP-0146, and EP-0186, as well as the monoclonal antibody EP-9001A completing phase 1b clinical trials [2] - Strategic investments are accelerating the company's innovation transformation, including an increase in equity investment in Shanghai Chaoyang Pharmaceutical to 30.68%, focusing on oncology and autoimmune areas [2] Profit Forecast - The company is expected to achieve revenues of 1.501 billion yuan, 1.795 billion yuan, and 2.202 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 11.2%, 19.6%, and 22.7% [3] - The forecasted net profit for the same years is 282 million yuan, 345 million yuan, and 431 million yuan, with growth rates of 18.2%, 22.5%, and 24.8% respectively [3]

Group 1: Yuan Dong Bio - In the first half of 2025, Yuan Dong Bio achieved revenue of 654 million yuan, a year-on-year decrease of 2.25% [1] - The net profit attributable to shareholders was 137 million yuan, down 6.77% year-on-year, but excluding stock incentive costs, it showed a slight increase of 0.28% [1] - R&D investment was approximately 133 million yuan, accounting for 20.25% of revenue, with new drug R&D investment amounting to 44.83 million yuan, representing 33.83% of total R&D expenditure [1] - The company is responding to centralized procurement policies by enhancing innovation, deepening transformation, and improving operational efficiency across the value chain [1] - The ADC innovative drug YLSH003 has completed preclinical research and IND application, while HP-001 is undergoing Phase I clinical trials with overall safety deemed good [1] Group 2: Fei Ling Ke Si - In the first half of 2025, Fei Ling Ke Si focused on its core business while actively expanding new products and clients [2] - The top five customers accounted for 96.77% of the company's revenue, with data center switch sales increasing by 67% year-on-year [2] - R&D investment was 71.89 million yuan, making up 9.96% of revenue, and the company has completed multiple product iterations and upgrades [2] - The overseas market generated sales revenue of 15.18 million yuan, primarily through collaborations with clients in Japan and South Korea [2] - The Zhejiang Haining production base achieved revenue of 171 million yuan with a net profit of 2.86 million yuan [2]

Group 1 - The core viewpoint of the news is that KaiFeng Investment has conducted research on YuanDong Bio, revealing a decline in revenue and net profit for the first half of 2025, alongside ongoing clinical trials for new drugs [1] - YuanDong Bio achieved operating revenue of 654 million yuan, a year-on-year decrease of 2.25%, and a net profit attributable to shareholders of 137 million yuan, down 6.77% year-on-year, although excluding stock incentive costs, there was a slight increase of 0.28% [1] - The company's R&D investment was approximately 133 million yuan, accounting for 20.25% of operating revenue, with new drug R&D expenditures amounting to 44.83 million yuan, representing 33.83% of total R&D investment [1] Group 2 - The international business of YuanDong Bio includes APIs and formulations, with multiple products either registered or submitted for registration [1] - The API and CDMO segment generated operating revenue of 87 million yuan, reflecting a year-on-year growth of 3.17%, although the growth rate has slowed [1] - YuanDong Bio is responding to the impact of centralized procurement policies by enhancing innovation, deepening transformation, and improving operational efficiency across the entire value chain [1] Group 3 - The HP-001 drug is currently undergoing Phase I clinical trials, showing overall good safety [1] - The ADC innovative drug YLSH003 has completed preclinical research and IND submission [1] - The extended-release acetaminophen and morphine sulfate naloxone capsules have been submitted for production and are currently under review [1]

根据市场公开信息及8月20日披露的机构调研信息，知名私募世诚投资近期对2家上市公司进行了调研，相关名单如下： 1）苑东生物 （上海世诚投资参与公司特定对象调研） 调研纪要：2025年上半年，苑东生物实现营业收入6.54亿元，同比减少2.25%；归母净利润1.37亿元，同比减少6.77%，剔除股权激励费用影响， 同比增长0.28%。研发投入约1.33亿元，占营业收入比例为20.25%，新药研发投入金额为4,482.59万元，占总体研发投入比例为33.83%。国际化业 务涵盖原料药和制剂，多个产品完成注册或提交注册。原料药及CDMO板块实现营业收入0.87亿元，同比增长3.17%，增速放缓。公司通过强化创 新驱动、深化仿创转型、全价值链提升运营效率等举措应对集采政策影响。HP-001正在进行一期临床试验，整体安全性良好。ADC创新药 YLSH003已完成临床前研究及IND申报。氨酚羟考酮缓释片和硫酸吗啡盐酸纳曲酮缓释胶囊均已申报生产，目前正在审评中。 2）山金国际 （世诚投资参与公司业绩说明会&线上会议） 调研纪要：山金国际介绍了公司2023年上半年矿产金产量情况，尽管产量低于去年同期，但公司采取多种措施争取下半 ...